Inherited Cancer Syndromes and the DNA Damage Response
|
|
- Carol Washington
- 5 years ago
- Views:
Transcription
1 Inherited Cancer Syndromes and the DNA Damage Response
2 Inherited Breast Cancer and DNA Double- Strand Break Repair Michal Goldberg Department of GeneGcs The Hebrew University Cancer Hub, March 2014
3 Hallmarks of cancer cells MutaGon accumulagon Chromosomal instability Changes in the structure and number of chromosomes Hanahan and Weinberg. Cell, 2011
4 Hallmarks of cancer cells Hanahan and Weinberg. Cell, 2011
5 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents X DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Genomic instability Bulky adduct Thymidine dimers Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Interstrand cross- link Double- strand break Homologous recombinagon Non- homologous end joining Mismatch Inser;on/dele;on Double- strand break Mismatch repair Negri5o. Nature Educa;on 3(9):26
6 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Bulky adduct Thymidine dimers Interstrand cross- link Double- strand break Mismatch Inser;on/dele;on Double- strand break Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Homologous recombinagon Non- homologous end joining Mismatch repair Negri5o. Nature Educa;on 3(9):26
7 DNA damage and DNA repair Damaging agents (internal and external) X- rays Oxygen radicals AlkylaGng agents DDR UV light AromaGc compounds X- ray RadiomimeGc drugs ReplicaGon errors Collapse of the replicagon fork The DNA damage response Uracil Abasic site 8- Oxoguanine Single- strand break Bulky adduct Thymidine dimers Interstrand cross- link Double- strand break Mismatch Inser;on/dele;on Double- strand break Checkpoint DNA Apoptosis / acgvagon Base- excision repair NucleoGde- excision Senescence repair (BER) repair (NER) Homologous recombinagon Non- homologous end joining Mismatch repair Negri5o. Nature Educa;on 3(9):26
8 DNA double- strand break (DSB) repair Resec;on of the 5ʹ strands to generate 3ʹ single- stranded DNA HR Homologous recombinagon ; NHEJ Non- homologous end joining ; SSA Single- strand annealing ; BIR break- induced replicagon ; DSBR HR repair ; SDSA Synthesis- dependent strand- annealing Aguilera & Gómez- González, Nat. Rev. Genet (2008)
9 DSB repair and genomic instability Aguilera & Gómez- González, Nat. Rev. Genet (2008)
10 DSB repair and genomic instability Repair impairment Aguilera & Gómez- González, Nat. Rev. Genet (2008)
11 Familial Breast Cancer and DNA DSB Repair
12 Breast cancer suscepgbility genes Apostolou & Fos;ra. Biomed Res Int. (2013)
13 HR repair genes and inherited breast cancer Aguilera & Gómez- González, Nat. Rev. Genet (2008)
14 HR repair genes and inherited breast cancer Zhang & Powell. Mol Cancer Res. (2005) Adapted from: Mladenov et al. Fornt Oncol (2013)
15 Screen for DDR genes involved in estrogen- dependent cancers Genes that are upregulated by estrogen Genes that have a role in the DNA damage response SelecGon for driver mutagons in breast and ovarian cancers Strauss et al. Unpublished Carmit Strauss
16 HR repair genes and inherited breast cancer # Zhang & Powell. Mol Cancer Res. (2005) # Strauss et al. Unpublished BRCA2 = FANCD1 PALB2 = FANCN Adapted from: Mladenov et al. Fornt Oncol (2013)
17 Genes predisposing to breast cancer are mutated in fanconi anemia ICL (interstrand crosslinks) BACH1 = BRIP1 = FANCJ Branzei & Foiani. Nat Rev Mol Cell Biol. (2010)
18 HR repair genes and inherited breast cancer why breast cancer??? Mladenov et al. Fornt Oncol (2013)
19 Estrogen acgvity Droog et al., Eur J Pharmacol. 2013
20 Estrogen- induced DNA repair genes Adapted from: Mladenov et al. Fornt Oncol (2013)
21 Screen for DDR genes involved in estrogen- dependent cancers Genes that are upregulated by estrogen Genes that have a role in the DNA damage response SelecGon for driver mutagons in breast and ovarian cancers Strauss et al. Unpublished Carmit Strauss
22 Estrogen- induced DNA repair genes # # # # # # # Strauss et al. Unpublished Adapted from: Mladenov et al. Fornt Oncol (2013)
23 Estrogen induces DSBs at promoters of estrogen- induced genes Williamson & Lees- Miller. Carcinogenesis (2011)
24 Genomic instability due to DSBs at estrogen- responding genes Inherited mutagon in HR repair gene, regulated by estrogen HR repair gene, regulated by estrogen
25 Genomic instability due to DSBs at estrogen- responding genes Estrogen
26 Genomic instability due to DSBs at estrogen- responding genes Estrogen
27 DNA repair genes and cancer Adapted from: Berger et al., Nature (2011)
28 DNA double- strand break (DSB) repair Aguilera & Gómez- González, Nat. Rev. Genet (2008)
29 Genomic instability due to DSBs at estrogen- responding genes DSB repair Terminal delegon MitoGc recombinagon Small insergon/ delegon or a point mutagon Gene conversion TranslocaGon
30 DNA repair genes and cancer Adapted from: Berger et al., Nature (2011)
31 Genomic instability due to DSBs at estrogen- responding genes DSB repair Terminal delegon Small insergon/ delegon or a point mutagon TranslocaGon
32 HR repair genes and cancer HR repair gene B HR repair gene C Adapted from: Berger et al., Nature (2011)
33 A model: HR repair genes and estrogen- dependent cancers Promotes proliferagon Estrogen Upregulates HR repair gene expression Inherited mutagon (heterozygous) in HR repair gene Genomic instability Estrogen DSB formagon at promoters of E2- upregulated genes
34 HR repair genes and inherited breast cancer Treatment # # Strauss et al. Unpublished Adapted from: Mladenov et al. Fornt Oncol (2013)
35 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) Adapted from: Itamochi, World Biol Chem (2010)
36 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) Adapted from: Itamochi, World Biol Chem (2010)
37 PARP inhibitors Cur;n, Biochem Soc Trans (2014)
38 PARP inhibitors Chen et al, Arch Gynecol Obstet (2013) IV intravenous PO - oral
39 Single- strand break repair and poly (ADP- ribose) polymerase (PARP) PARPi resistance Adapted from: Itamochi, World Biol Chem (2010)
40
41
Inhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationDNA/RNA: polynucleotide chains
What is DNA? DNA/RNA: polynucleotide chains Phosphate Base Sugar (2 OH=ribose, 2 H=deoxyribose) Nucleotide =sugar+phosphate+base DNA is a double helix DNA damage and repair How is DNA damaged? How is DNA
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationDNA repair and synthetic lethality
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2011 DNA repair and synthetic lethality Gong-she Guo Shandong University Feng-mei Zhang Shandong University Rui-jie
More informationBiochemistry 201: DNA repair January 24, 26, 2000 Gilbert Chu
1) Why study DNA repair? Biochemistry 201: DNA repair January 24, 26, 2000 Gilbert Chu The genome is assaulted by a myriad of different agents that cause DNA damage. Sources of damage can be both exogenous
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationTargeting DNA base excision repair: a new strategy for personalised cancer therapy
GOULSTONIAN LECTURE Clinical Medicine 2012, Vol 12, No 6: s42 s46 Targeting DNA base excision repair: a new strategy for personalised cancer therapy Rachel Abbotts and Srinivasan Madhusudan Introduction
More informationDrugging the Cancers Addicted to DNA Repair
JNCI J Natl Cancer Inst (2017) 109(11): djx059 doi: 10.1093/jnci/djx059 First published online May 18, 2017 Review Drugging the Cancers Addicted to DNA Repair Jac A. Nickoloff, Dennie Jones, Suk-Hee Lee,
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D. Chief Scientific Officer Trevigen, Inc. Gaithersburg, MD Poly(ADP-ribose) polymerases are promising therapeutic targets. In response
More informationTargeting the ATR Kinase in Cancer Therapy
Targeting the ATR Kinase in Cancer Therapy 2017 Chabner Colloquium October 30, 2017 Lee Zou MGH Cancer Center Harvard Medical School Disclosure Consultant/advisory role: Loxo Oncology DNA Damage and Replication
More informationMutagenesis. David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill.
Mutagenesis David M. DeMarini, Ph.D. University of North Carolina at Chapel Hill ddemarini@nc.rr.com 1. DNA as the Target Mutagenesis Overview 2. DNA Damage (The Mutagenesis Paradigm) A. Types of Damage
More informationPrognostic value of DNA repair based stratification of hepatocellular carcinoma
Prognostic value of DNA repair based stratification of hepatocellular carcinoma Zhuo Lin 1, 2 #, Shi-Hao Xu 3 #, Hai-Qing Wang 4, Yi-Jing Cai 1, 2, Li Ying 3, Mei Song 1, 2, Yu-Qun Wang 1, 2, Shan-Jie
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationChapter 9. Cells Grow and Reproduce
Chapter 9 Cells Grow and Reproduce DNA Replication DNA polymerase Addition of a nucleotide to the 3 end of a growing strand Use dntps as substrate Release of pyrophosphate Initiation of Replication Replication
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationVariants in DNA Repair Genes and Glioblastoma. Roberta McKean-Cowdin, PhD
Variants in DNA Repair Genes and Glioblastoma Advances in Bioinformatics and Genomics Symposium February 19, 2010 Roberta McKean-Cowdin, PhD Department of Preventive Medicine, University of Southern California
More informationGenomic instability. Amin Mahpour
Genomic instability Amin Mahpour 1 Some questions to ponder What is Genomic instability? What factors contribute to the genomic integrity? How we identify these aberrations? 2 PART I: MOLECULAR BIOLOGY
More informationRepair of Broken Chromosomes and Maintenance of Chromosome Stability
Repair of Broken Chromosomes and Maintenance of Chromosome Stability Jim Haber Brandeis University Genome instability in tumor cells Truncations Translocations Inversions Duplications Amplifications Deletions
More informationUniversity of Groningen
University of Groningen Therapeutic targeting and patient selection for cancers with homologous recombination defects Talens, Francien; Jalving, Mathilde; Gietema, Jourik A.; van Vlugt, Marcel A. T. M.
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationDNA damage and DNA repair
DNA damage and DNA repair Susan P. Lees-Miller, PhD, Professor, Departments of Biochemistry & Molecular Biology and Oncology, Southern Alberta Cancer Research Institute, University of Calgary, Calgary,
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationBRCA1, a complex protein involved in the maintenance of genomic stability
STATE-OF-THE-ART REVIEW BRCA1, a complex protein involved in the maintenance of genomic stability Kienan I. Savage and D. Paul Harkin Centre for Cancer Research and Cell Biology, Queen s University Belfast,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationReview Article DNA Damage as a Driver for Growth Delay: Chromosome Instability Syndromes with Intrauterine Growth Retardation
Hindawi BioMed Research International Volume 2017, Article ID 8193892, 14 pages https://doi.org/10.1155/2017/8193892 Review Article DNA Damage as a Driver for Growth Delay: Chromosome Instability Syndromes
More informationMugimane Manjanatha, Ph.D
Genotoxicity of Doxorubicin in F344 Rats by Combining the Comet Assay, Peripheral Blood Micronucleus Test, and Pathway-Focused Gene Expression Profiling Mugimane Manjanatha, Ph.D FDA/NCTR/DGMT DISCLAIMER
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0484 TITLE: PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING ORGANIZATION: University of Washington REPORT DATE: 2014 TYPE OF REPORT: Annual Report PREPARED FOR: U.S. Army
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationTOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad
TOUR REPORT Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad 1. Name and Designation of ICMR IF : Dr. A. Venkateshwari, Assistant Professor 2. Address: Dr.
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationMUTATIONS, MUTAGENESIS, AND CARCINOGENESIS. (Start your clickers)
MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS (Start your clickers) How do mutations arise? And how do they affect a cell and its organism? Mutations: heritable changes in genes Mutations occur in DNA But
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationJill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
More informationEx vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent
Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationPersonalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil
Personalised Medicine in Practice Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Cancer Care Personalised Medicine in Cancer Care
More informationDissection of breast cancer development and therapy resistance in mouse models. Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
Dissection of breast cancer development and therapy resistance in mouse models Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands GEMMs of human cancer Genetically engineered mouse models
More informationTargeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017
Targeted therapy & Tumor molecular profile Anton Tikhonov V Bioinformatics Summer School, 2017 What exactly is targeted therapy? It has target It was rationally designed Its target was discovered before
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationOvarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects
Int. J. Mol. Sci. 2013, 14, 640-673; doi:10.3390/ijms14010640 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Ovarian Cancer: In Search of Better
More informationPoly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer
Showa Univ J Med Sci 25 2, 83 91, June 2013 Original Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer Genki TSUKUDA 1 2, Yuko DATE 1, Kunio ASONUMA
More informationObjectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
More informationUpdate on Poly ADP ribose polymerase inhibition for ovarian cancer treatment
DOI 10.1186/s12967-016-1027-1 Journal of Translational Medicine REVIEW Open Access Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment Anselmo Papa 1*, Davide Caruso 1, Martina
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationNext Generation DDR Therapeutics
Next Generation DDR Therapeutics Q3 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects
More information6.3 DNA Mutations. SBI4U Ms. Ho-Lau
6.3 DNA Mutations SBI4U Ms. Ho-Lau DNA Mutations Gene expression can be affected by errors that occur during DNA replication. Some errors are repaired, but others can become mutations (changes in the nucleotide
More informationBreast & Colon Cancer: Molecular Alterations & Therapeutic Targets Part 1
Breast & Colon Cancer: Molecular Alterations & Therapeutic Targets Part 1 Nancy Hynes FMI June 1, 2007 Molecular targets for cancer therapy In the past 25 yrs cancer research has generated a large body
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationHide-then-hit to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer
doi:10.1093/jmcb/mjq054 Journal of Molecular Cell Biology (2011), 3, 59 65 59 Review Hide-then-hit to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationPARP AND PROSTATE CANCER
PARP AND PROSTATE CANCER Terrence P McGarty White Paper No 143 February 2017 DNA breaks often lead to Cancer. Double strand breaks are handled by BRCA gene products and Single strand breaks by PARP products.
More informationRecrui ng now. Could you help by joining this study?
Pancrea c cancer POLO study Recrui ng now AstraZeneca is looking for people with BRCA-mutated metasta c pancrea c cancer to join POLO, a clinical study to help scien sts find be er treatments for this disease
More informationDNA Damage Response Genes and the Development of Cancer Metastasis
DNA Damage Response Genes and the Development of Cancer Metastasis Authors: Constantinos G. Broustas, and Howard B. Lieberman Source: Radiation Research, 181(2) : 111-130 Published By: Radiation Research
More informationAssociation between ERCC1 and XPF polymorphisms and risk of colorectal cancer
Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer H. Yang, G. Li and W.F. Li Departments of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationMUTATIONS, MUTAGENESIS, AND CARCINOGENESIS
MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS How do different alleles arise? ( allele : form of a gene; specific base sequence at a site on DNA) Mutations: heritable changes in genes Mutations occur in DNA
More informationCellular response to DNA interstrand crosslinks: the Fanconi anemia pathway
Cell. Mol. Life Sci. (2016) 73:3097 3114 DOI 10.1007/s00018-016-2218-x Cellular and Molecular Life Sciences REVIEW Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway David Lopez-Martinez
More informationGENE EXPRESSION. Amoeba Sisters video 3pk9YVo. Individuality & Mutations
Amoeba Sisters video https://www.youtube.com/watch?v=giez 3pk9YVo GENE EXPRESSION Individuality & Mutations Complete video handout http://www.amoebasisters.com/uploads/ 2/1/9/0/21902384/video_recap_of_muta
More informationDNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations. Peter de Boer
DNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations Peter de Boer Department of Obst.& Gynaecology, Div. Reproductive Medicine Radboud University Nijmegen Medical
More informationSurveying the Human Genome for Genetic Markers Associated with the Mutator Phenotype and Chromosomal Instability. Timothy Lee
Surveying the Human Genome for Genetic Markers Associated with the Mutator Phenotype and Chromosomal Instability by Timothy Lee A thesis submitted in conformity with the requirements for the degree of
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationLearning Objectives. Page 1
Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in
More informationXRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis
ONCOLOGY LETTERS 9: 2425-2429, 2015 XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis JINGHUA FAN 1, YUHUA FAN 2, XIAOXIAO KANG 1 and LIMIN ZHAO 1 1 Department of Dermatology, Xi'an
More informationPRINCIPAL INVESTIGATOR: Robert L. Nussbaum, MD. CONTRACTING ORGANIZATION: University of California San Francisco San Francisco, CA 94103
Award Number: W81XWH-12-1-0569 TITLE: Functional Analysis of Variants of Unknown Significance in BRCA1 and BRCA2 Using Complementation of a Synthetic Lethal Interaction with PARP Inhibition PRINCIPAL INVESTIGATOR:
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationMale Factor Infertility and Health. Karen Baker, MD Associate Professor Duke University, Division of Urology
Male Factor Infertility and Health Karen Baker, MD Associate Professor Duke University, Division of Urology Fertility and Cancer Heart disease Metabolic syndrome Diabetes Early death Goals: Review literature
More informationPHD STUDENTSHIP PROJECT PROPOSAL
The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL PROJECT DETAILS Project Title: Short Project Title: SUPERVISORY TEAM Primary Supervisor(s): Understanding therapeutic responses in BRCA
More informationUnderstanding Biological Activity to Inform Drug Development
National Cancer Policy Forum Understanding Biological Activity to Inform Drug Development December 12, 2016 Wolfgang Weber Molecular Imaging and Therapy Service Department of Radiology RECIST Response
More informationSpring 2015 Module 2 System Engineering and Protein Founda<ons
20.109 Spring 2015 Module 2 System Engineering and Protein Founda
More informationTumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition
Tumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition Andrew J Massey Supplementary Information Supplementary Figure S1. Related to Fig. 1. (a) HT29 or U2OS cells
More informationRESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER.
RESISTANCE RELATIONSHIPS BETWEEN PLATINUM AND PARP-INHIBITORS IN OVARIAN CANCER. Britta Stordal 1, Yidong Chen 2, Angela Farrelly 3, Danielle Gallagher 3, Steven Busschots 1, Mattia Cremona 3, Mark Carey
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationComputational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 11-16-2017 Computational Investigation of Homologous Recombination DNA Repair
More information609G: Concepts of Cancer Genetics and Treatments (3 credits)
Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,
More informationHereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors. Vanessa Miraj Stuyvesant High School May 20,2013
+ Hereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors Vanessa Miraj Stuyvesant High School May 20,2013 + Physiology q 3-10% of breast or ovarian cancers are considered
More information5/25/2015. Replication fork. Replication fork. Replication fork. Replication fork
Mutations Chapter 5 Cellular Functions Lecture 3: and Cell Division Most DNA mutations alter the protein product May Make it function better (rarely) Change its function Reduce its function Make it non-functional
More informationRadiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica
Radiobiology of fractionated treatments: the classical approach and the 4 Rs Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology It is fundamental in radiation oncology Radiobiology
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More informationWO 2017/ Al. cc cc. 27 April 2017 ( ) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationDNA Repair and Resistance to Cancer Therapy
Chapter 18 DNA Repair and Resistance to Cancer Therapy António S. Rodrigues, Bruno Costa Gomes, Célia Martins, Marta Gromicho, Nuno G. Oliveira, Patrícia S. Guerreiro and José Rueff Additional information
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationCancer statistics (US)
Disclosure I have no financial relationships to disclose Biology and Introduction to the Genetics of Cancer Vickie Matthias Hagen, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationImmune therapy for women with recurrent ovarian cancer
Immune therapy for women with recurrent ovarian cancer Sarah Adams, MD Associate Professor, Division of Gynecologic Oncology University of New Mexico Comprehensive Cancer Center The problem: overall survival
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More information